<DOC>
	<DOCNO>NCT00777959</DOCNO>
	<brief_summary>This study look see combination ridaforolimus bicalutamide work well placebo bicalutamide men prostate cancer .</brief_summary>
	<brief_title>Bicalutamide Ridaforolimus Men With Prostate Cancer ( MK-8669-002 )</brief_title>
	<detailed_description>Ridaforolimus ( MK8669/AP23573 ) also know deforolimus May 2009 .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Confirmed adenocarcinoma prostate . Evidence metastatic disease Evidence disease progression include one following : increasing level PSA , progressive lymph node disease , worsen bone scan PSA level great equal 7 ng/ml . ECOG performance status less equal 1 Exclusion Criteria : Previously receive bicalutamide , flutamide , nilutamide within past 12 month ( except period use le 30 day long ) . Prior chemotherapy prostate cancer Prior rapamycin rapamycin analog , include ridaforolimus , everolimus , temsirolimus . Patient receive opioid narcotic analgesic pain due prostate cancer Patient pain related prostate cancer warrant initiation chemotherapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>